Back to today’s briefing

Story perspectives

Biotech Stocks Rally Amid Challenges and Record Earnings

1/10/2025

38 7

Summary

Story summary

Biotech stocks face challenges following Trump's appointment of Robert F. Kennedy Jr. as HHS head, impacting Pfizer and Moderna.
Exelixis, Corcept, ADMA Biologics, and Ligand report impressive earnings growth and optimistic sales projections.
United Therapeutics achieves record highs, fueled by robust sales of its PAH treatment, Tyvaso.
Analysts suggest keeping an eye on select biotech stocks for potential investment opportunities.

History

Historical Context

The current challenges facing biotech stocks echo the late 1990s dot-com bubble burst. Just as tech stocks plummeted after overvaluation, today's biotech sector faces uncertainty amid political shifts. Historical investor caution signals a need for careful analysis of emerging biotech opportunities, reminiscent of past market corrections.

1 of 2

Story summary

Biotech stocks face challenges following Trump's appointment of Robert F. Kennedy Jr. as HHS head, impacting Pfizer and Moderna.
Exelixis, Corcept, ADMA Biologics, and Ligand report impressive earnings growth and optimistic sales projections.
United Therapeutics achieves record highs, fueled by robust sales of its PAH treatment, Tyvaso.
Analysts suggest keeping an eye on select biotech stocks for potential investment opportunities.

1 / 2